Last update 08 May 2025

CD22 positive Follicular Lymphoma

Basic Info

Synonyms-
Introduction-

Related

1
Drugs associated with CD22 positive Follicular Lymphoma
Inotuzumab Ozogamicin
Target
CD22 x DNA
Mechanism
CD22 inhibitors [+1]
Active Org.
Pfizer Pharmaceuticals Korea Ltd. [+4]
Originator Org.
Pfizer Inc.Pfizer Inc.
Active Indication
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia [+10]
Inactive Indication
Aggressive Non-Hodgkin Lymphoma [+10]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
European Union [+3]
First Approval Date28 Jun 2017
1
Clinical Trials associated with CD22 positive Follicular Lymphoma
NCT00562965
/ TerminatedPhase 3
An Open-label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin (Cmc-544) Administered In Combination With Rituximab Compared To A Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory, Cd22- Positive, Follicular B-cell Non Hodgkin's Lymphoma
100 Clinical Results associated with CD22 positive Follicular Lymphoma
Login to view more data
100 Translational Medicine associated with CD22 positive Follicular Lymphoma
Login to view more data
0 Patents (Medical) associated with CD22 positive Follicular Lymphoma
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free